<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: -Catheter ablation of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) in non-<z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart diseases</z:e> can be challenging and outcomes across different diseases are incompletely defined </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study is to describe the outcomes following catheter ablation for non-ischemic VT in a large cohort and compare the electrophysiological findings and outcomes according to the type of underlying disease </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: -Of 891 consecutive patients undergoing catheter ablation for <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, 226 patients (52±14 yrs, 79% male) with sustained VT due to non-<z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> were included </plain></SENT>
<SENT sid="3" pm="."><plain>The primary endpoint was <z:hpo ids='HP_0000001'>all</z:hpo>-cause <z:hpo ids='HP_0011420'>death</z:hpo> or heart transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>Secondary endpoints were a composite of <z:hpo ids='HP_0011420'>death</z:hpo>, heart transplantation or readmission due to VT recurrence within 1 year of discharge </plain></SENT>
<SENT sid="5" pm="."><plain>Underlying <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart diseases</z:e> were <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo>(<z:chebi fb="20" ids="15767">DCM</z:chebi>) in 119(53%), <z:hpo ids='HP_0001654'>valvular heart disease</z:hpo> in 34(15%), <z:hpo ids='HP_0011663'>arrhythmogenic right ventricular cardiomyopathy</z:hpo>(ARVC) in 37(16%), <z:hpo ids='HP_0002564'>congenital heart disease</z:hpo> in 16(7%), <z:e sem="disease" ids="C0392077" disease_type="Disease or Syndrome" abbrv="">cardiac sarcoidosis</z:e> in 13(6%) and <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> in 7(3%) </plain></SENT>
<SENT sid="6" pm="."><plain>After ablation inability to induce any VT was achieved in 55% and another 20% had inducible VTs modified </plain></SENT>
<SENT sid="7" pm="."><plain>Major complications occurred in 5% </plain></SENT>
<SENT sid="8" pm="."><plain>ARVC had better outcomes than <z:chebi fb="20" ids="15767">DCM</z:chebi> for primary(P=0.002) and secondary endpoint(P=0.004) </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">Sarcoidosis</z:e> had worse outcome than <z:chebi fb="20" ids="15767">DCM</z:chebi> for secondary endpoint (P=0.002) </plain></SENT>
<SENT sid="10" pm="."><plain>At 1 year after the last ablation (a mean of 1.4±0.6 procedures, 1 to 4), freedom from <z:hpo ids='HP_0011420'>death</z:hpo>, heart transplantation, and readmission for VT recurrence was achieved in 173(77%) patients </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: -In patients with recurrent VT due to nonischemic <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e>, catheter ablation is often useful, although the outcome varies according to the nature of the underlying <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> </plain></SENT>
</text></document>